Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Earnings Routine +

Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results

Helus Pharma burns cash faster in Phase 3 ramp but secures $50M runway as HLP003 nears topline readout

By The Northwire Desk — AI Analysis Jun 29, 2026 · 07:40 HELP · 9.2 Contakt World Technologies Corp.
Executive Summary
  • Helus Pharma reported audited financial results for the fiscal year ended March 31, 2026, showing a net loss of $148.0 million ($47.0 million in Q4), compared to $81.6 million in the prior year.
  • Cash-based operating expenses (R&D, G&A) rose to $131.7 million for the year ($42.6 million in Q4), reflecting the operational scaling required for Phase 3 execution.
  • Cash flows used in operating activities were $133.3 million for the year ($37.3 million in Q4).
  • The company closed a $50 million underwritten equity offering on June 25, 2026, at $4.85 per share, bringing total cash to $157.3 million as of March 31, 2026.
  • Pipeline updates indicate the HLP003 (MDD) APPROACH Phase 3 trial has surpassed 88% enrollment, maintaining the Q4 2026 topline data timeline.
  • HLP004 (GAD) reported positive Phase 2 signal detection results, showing clinically meaningful improvement over standard of care.
  • Leadership transition: Eric So returns as Interim CEO following Michael Cola's departure in April 2026.
Material Impact
  • The $50 million capital raise is a standard, expected financing move for a clinical-stage biotech funding pivotal trials. It extends the cash runway but introduces near-term dilution.
  • The widening net loss ($148M vs $81.6M) and accelerated cash burn are consistent with the planned ramp-up of Phase 3 clinical operations and do not indicate operational mismanagement.
  • HLP003 enrollment at >88% de-risks the Q4 2026 catalyst and confirms execution capability. HLP004's positive Phase 2 data provides a secondary commercial option but does not alter the primary valuation driver.
  • The CEO transition introduces governance uncertainty, but the return of the co-founder mitigates immediate strategic disruption.
HELP · Price
Company Overview
  • Helus Pharma (formerly Cybin Inc.) is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs) for mental health conditions, primarily Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD).
  • Lead asset HLP003 is in Phase 3 development for MDD, holding FDA Breakthrough Therapy designation.
  • HLP004 is in Phase 2 for GAD, utilizing an intramuscular delivery system optimized for clinical scalability.
  • The company operates under a rebranded identity, trading on Nasdaq under the ticker HELP, with a strong IP portfolio protected through 2041.
Read the original news release →

More from Contakt World Technologies Corp.

Jun 25, 2026 · 19:03

Helus Pharma closes $50M equity offering to fund Phase 3 MDD readout in Q4 2026, extending cash runway amid leadership transition.

Financings Jun 24, 2026 · 06:01

Helus Pharma(TM) Announces US$50 Million Underwritten Offering

Financings Jun 24, 2026 · 06:00

Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress

Regulatory Apr 28, 2026 · 07:30

Leadership Transition and Recruitment Partnership

M&A / Property Apr 20, 2026 · 08:15

Management Instability Clouds Near-Term Catalysts Despite Strong Cash Position

Regulatory Apr 20, 2026 · 08:00

Tagline: Leadership Turmoil Overshadows Clinical Wins as Helus Pharma CEO Departs Ahead of Pivotal Phase 3 Readout

Management